Rx Drug DTC Advertising: ‘Europe Is A Minefield’ With LinkedIn Posts Triggering Slew Of Complaints
Executive Summary
UK body overseeing complaints about pharmaceutical materials has determined that merely liking a post on LinkedIn is promotion. The Prescription Medicines Code of Practice Authority (PMCPA) has completed review of more than 50 complaints about LinkedIn posts.
You may also be interested in...
UK Guidance Tackles Social Media ‘Compliance Headache’ For Pharma
Announcing product milestones and liking LinkedIn posts are just some of the topics addressed in a long-awaited guidance that deals with the challenges prescription drug makers face in the UK when using social media.
Companies Reveal Hurdles In Providing Drugs Via Expanded Access Programs
GSK, Stealth BioTherapeutics and Blueprint Medicines discuss the difficulties getting participation of physicians, the excessive cost of expanded access, and whether physicians should report research data.
Current Pathways For Rare Disease Drugs Are Not Optimal, US FDA’s Califf Says
Anticipating a ‘tsunami of therapies’ for rare diseases, commissioner says the agency will have to think of creative approaches and employ regulatory flexibility for them. FDA considers copying the oncology center’s Project Facilitate for expanded access to other diseases.